Back to Search
ANDREW BERCHUCK MD
MD
Gynecologic Oncology Physician
NPI: 1154349181IndividualAccepts Medicare
Specialties, Licenses & Credentials
Gynecologic Oncology PhysicianPrimary
Obstetrics & Gynecology — Gynecologic Oncology
Code: 207VX0201X
31435(NC)
Education
CLVLND CLINIC LERNER COLLEGE OF MED OF CASE WSTN RSV UNIVERSITY
Class of 1980
Research & Publications (20)
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
PMID 19318476·Clin Cancer Res·2009
4-observational
Consortium analysis of 7 candidate SNPs for ovarian cancer.
PMID 18431743·Int J Cancer·2008
4-observational
Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium.
PMID 18546618·Adv Exp Med Biol·2008
6-review
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
PMID 15897565·Clin Cancer Res·2005
8-other
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
PMID 15598772·Cancer Epidemiol Biomarkers Prev·2004
8-other
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
PMID 15118612·Am J Obstet Gynecol·2004
8-other
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
PMID 19642140·Int J Cancer·2010
8-other
Ovarian cancer risk factors in African-American and white women.
PMID 19605513·Am J Epidemiol·2009
8-other
Role of genetic polymorphisms and ovarian cancer susceptibility.
PMID 19383379·Mol Oncol·2009
6-review
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.
PMID 19304784·Hum Mol Genet·2009
8-other
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.
PMID 19276375·Cancer Res·2009
8-other
MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.
PMID 19603033·Br J Cancer·2009
8-other
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
PMID 19127255·Br J Cancer·2009
4-observational
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
PMID 18836486·Oncogene·2009
7-preclinical
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
PMID 19135712·Gynecol Oncol·2009
3-trial
Yin yang 1 modulates taxane response in epithelial ovarian cancer.
PMID 19208743·Mol Cancer Res·2009
4-observational
Relationship between tamoxifen use and high risk endometrial cancer histologic types.
PMID 18937966·Gynecol Oncol·2009
8-other
Evaluation of two management strategies for preoperative grade 1 endometrial cancer.
PMID 19546752·Obstet Gynecol·2009
4-observational
Microarray analysis of gene expression in gynecologic cancers--still only the beginning.
PMID 19497432·Gynecol Oncol·2009
8-other
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
PMID 19174584·Cancer Prev Res (Phila)·2009
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 20 DUKE MEDICINE CIR
DURHAM, NC 27710 - Phone
- (919) 684-8111
Quick Facts
- NPI
- 1154349181
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 46
- Publications
- 20
Are you this provider?
Claim Your Profile